Pharmaceuticals, Biotechnology and Life Sciences
Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 4:30 p.m. ETArcutis management will also participate…
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and…
Oral presentation at ASN on lead program, ABO-101 for primary hyperoxaluria type 1 (PH1), supporting in vivo proof of pharmacology.…
MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing…
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new…
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with…
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is…
Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New…
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician’s choice of immune checkpoint…